Diamyd Medical says retogatein delays insulin need by 5.6 years in prevention trial responder group

Diamyd Medical reported randomized placebo-controlled Immune Tolerance Trial results, saying retogatein delayed the need for insulin by 5.6 years in treatment responders, with a favorable safety profile and a two-injection regimen.